StockNews.com Begins Coverage on InspireMD (NYSE:NSPR)

Equities research analysts at StockNews.com started coverage on shares of InspireMD (NYSE:NSPR) in a report released on Sunday. The brokerage set a “sell” rating on the stock.

A number of other brokerages have also commented on NSPR. Piper Sandler reaffirmed an “overweight” rating and set a $4.50 price objective on shares of InspireMD in a research report on Tuesday, September 17th. Lake Street Capital started coverage on InspireMD in a report on Wednesday, December 11th. They issued a “buy” rating and a $5.00 price target for the company.

InspireMD Trading Up 1.9 %

Shares of InspireMD stock opened at $2.71 on Friday. InspireMD has a 1-year low of $1.81 and a 1-year high of $3.42. The firm has a fifty day simple moving average of $2.74 and a 200-day simple moving average of $2.70. The stock has a market capitalization of $70.69 million, a price-to-earnings ratio of -3.61 and a beta of 0.99.

InspireMD (NYSE:NSPR) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.20) by $0.04. The company had revenue of $1.81 million for the quarter, compared to the consensus estimate of $1.74 million. InspireMD had a negative return on equity of 69.42% and a negative net margin of 413.96%. During the same period last year, the business posted ($0.15) earnings per share. As a group, research analysts predict that InspireMD will post -0.79 earnings per share for the current year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in InspireMD stock. Parkman Healthcare Partners LLC purchased a new stake in InspireMD, Inc. (NYSE:NSPR) during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 104,081 shares of the company’s stock, valued at approximately $279,000. Parkman Healthcare Partners LLC owned approximately 0.42% of InspireMD at the end of the most recent reporting period. 44.78% of the stock is owned by institutional investors.

InspireMD Company Profile

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.